Biotechnology company Oxford BioDynamics, Plc (AIM: OBD) announced on Wednesday that clinical validation of its EpiSwitch Prostate Screening (PSE) test has been completed at its newly commissioned ISO15189 UK clinical laboratory. The move halves the turnaround time for PSE tests ordered by UK physicians, enhancing accessibility.
The PSE test, with 94% accuracy, combines PSA scores with proprietary epigenetic biomarkers to predict prostate cancer presence. The test aids in avoiding unnecessary biopsies for low-risk cases and prompts referrals for further investigation in high-risk instances.
OBD will soon validate its EpiSwitch Checkpoint Inhibitor Response Test (CiRT) within the UK facility, targeting immuno-oncology checkpoint inhibitor treatments. This advance bolsters OBD's precision medicine offerings, positioning it as a key player in the global biotechnology landscape.
Headquartered in Oxford, UK, Oxford BioDynamics is listed on AIM of the London Stock Exchange. With a robust technology portfolio and numerous partnerships, OBD is at the forefront of developing personalised healthcare solutions based on its proprietary EpiSwitch platform.
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Turnstone Biologics announces strategic restructuring
Pfizer's TALZENNA plus XTANDI shows promise in prostate cancer treatment
GenesisCare UK selects RayStation for radiotherapy system upgrade
Boehringer Ingelheim and Circle Pharma collaborate on cancer treatment
Petauri launches medical communications platform Petauri Advance
Bayer and MOMA Therapeutics enter oncology collaboration
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen